Diagnostics sales up in local currencies at Roche:
This article was originally published in Clinica
Diagnostics sales at Roche fell 10% to SwFr 490 million ($434 million) in the first quarter of 1995, compared with the same period last year. However, this masked a 4% rise in diagnostic sales in local currencies. At the end of April, shareholders approved Roche Biomedical Lab's merger with National Health Labs (see Clinica No 653, p 15). Group sales increased 2% in SwFr terms (15% in local currencies) to SwFr 5,075 million in the first quarter compared with the same period last year. This was due mainly to strong growth in pharmaceutical sales.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.